On Biostatistics and Clinical Trials
CQ's web blog on the issues in biostatistics and clinical trials.
Showing posts with label
Interim analysis
.
Show all posts
Showing posts with label
Interim analysis
.
Show all posts
Monday, February 16, 2026
The Statistical Magic Trick: How Trials Share Results While Staying Blind
›
In the world of clinical research, "breaking the blind" is typically a cardinal sin. Yet, high-stakes Phase 3 trials like ORIGIN...
Friday, March 03, 2023
Risk of Stopping Trial Early for Treatment Benefit - Story of Veru's Sabizabulin for Treatment of Covid
›
Today, we learned that FDA declined to approve the emergency use authorization (EUA) for Veru's sabizabulin for the treatment of Covid. ...
2 comments:
Sunday, January 09, 2022
Overrunning issue at the interim analysis for group sequential design
›
It is pretty common these days that clinical trials (especially the late phase, adequate, and well-controlled studies) employ interim analys...
1 comment:
Saturday, January 01, 2022
Futility Analysis and Conditional Power When Two Phase 3 Studies are Simultaneously Conducted
›
In late-phase clinical trials, an independent Data Monitoring Committee (DMC) is usually set up. If the clinical program includes multiple l...
›
Home
View web version
